Page 29 - Sciences Group News Today : Breaking News, Live Updates & Top Stories | Vimarsana

This article by Corey Noles was originally published on Cannabis & Tech Today, and appears here with permission. The UK is now the largest producer and exporter of legal cannabis in Europe, according to a new report. The report, released by released ResearchandMarkets.com, is titled   The European market is expected to reach $37 billion by 2027 from $3.5 billion in 2019; it is anticipated to grow at a CAGR of 29.6% from 2020 to 2027. The growth of the market in this region is attributed to the upgrading of regulations for medical cannabis and growth of the cannabis industry as well as an i...

European Cannabis Market Report 2020-2027: UK has Emerged as the Largest Producer and Exporter of Legalized Cannabis ResearchAndMarkets.com's offering. The Europe cannabis market is expected to reach US$ 36,997.1 million by 2027 from US$ 3,498.1 million in 2019; it is anticipated to grow at a CAGR of 29.6% from 2020 to 2027. The growth of the market in this region is attributed to the upgrading of regulations for medical cannabis and growth of the cannabis industry. However, challenges related to cannabis hinder the market growth. The European countries are experiencing transformation in t...

*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: 1. Obtains access to the information in a personal capacity; 2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services; 3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional bod...

SELLAS Announces Pricing of $16.2 Million Registered Direct Offering SELLAS Life Sciences Group Hamilton, BERMUDA NEW YORK, Dec. 13, 2020 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications, today announced that it has entered into a share purchase agreement with institutional investors to purchase approximately $16.2 million of its common stock in a registered direct off...

Week Ahead In Pharma: FDA Decision, Review Of COVID-19 Vaccine, Data Readouts (Moderna, BCRX, ARVN...) THOUSAND OAKS (dpa-AFX) - The week that just passed by saw a couple of stocks belonging to the healthcare sector record triple-digit gains and nearly a dozen managing to log gains in excess of 50 percent, thanks to positive clinical trial readouts. Greenwich LifeSciences Inc. (GLSI), which closed out the week at $56, delivering over 890%, was the top gainer of the week, following promising five year-data related to its drug candidate GP2 in a phase II clinical trial in HER2 positive women w...